With the clinic in sight, Greg Verdine's startup bags $178M for new class of targeted therapies
ARCH Venture Partners is buying into Greg Verdine’s vision for a world where no targets are off-limits — with the goal of finally pushing the first drug into the clinic.
The size of the Series D financing — $178 million — matches the grand ambitions FogPharma has sketched out with its Helicon compounds, a new class of polypeptide drugs it says combines the cell-penetrating capacity of small molecules with the target-engaging tenacity of biologics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.